2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
| Autor: | Cho, B.C., Lin, J., Camidge, D.R., Velcheti, V., Solomon, B., Lu, S., Lee, K.H., Kim, S.W., Kao, S., Diadziuskzko, R., Beg, M., Nagasaka, M., Felip, E., Besse, B., Springfeld, C., Popat, S., Wolf, J., Trone, D., Stopatschinskaja, S., Drilon, A. |
|---|---|
| Zdroj: | In European Journal of Cancer October 2022 174 Supplement 1:S1-S2 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect